Impact of the Timing of Enzyme Replacement Therapy Initiation and Cognitive Impairment Status on Outcomes for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review.

Yee, Karen S; Alexanderian, David; Feng, Yidie; Ren, Xiaowei; Schweikert, Bernd; Ayodele, Olulade

Yee, Karen S; Alexanderian, David; Feng, Yidie; Ren, Xiaowei; Schweikert, Bernd; Ayodele, Olulade.

Affiliation

Yee KS; Takeda Development Center Americas, Inc., Cambridge, Massachusetts.
Alexanderian D; Takeda Development Center Americas, Inc., Lexington, Massachusetts.
Feng Y; ICON plc, Vancouver, British Columbia, Canada.
Ren X; Takeda Development Center Americas, Inc., Cambridge, Massachusetts.
Schweikert B; ICON plc, Vancouver, British Columbia, Canada.
Ayodele O; Takeda Development Center Americas, Inc., Lexington, Massachusetts.

J Health Econ Outcomes Res ; 9(2): 67-76, 2022.

Article de En | MEDLINE | ID: mdl-36168594

Mots clés

Hunter syndrome; MPS II; cognitive impairment; disease burden; enzyme replacement therapy; idursulfase; lysosomal storage disease

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline Aspects: Patient_preference Langue: En Journal: J Health Econ Outcomes Res Année: 2022 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google